Neuronostics

Neuronostics develops digital biomarkers and software to improve the diagnosis of neurological conditions.

Exeter, UK—Founded 2018—Website

£2.4MTotal raised

Neuronostics is a medical technology start-up that develops mathematical and computational tools to improve the diagnosis and treatment of neurological conditions. Based in the UK, the company creates digital biomarkers like BioEP to enhance standard clinical recordings.

Founders

John Terry

Co-Founder

John brings academic and founding experience, serving as Managing Director of Neuronostics and Professor of Digital Health Innovation at the University of Plymouth. He previously held research and professorial roles at the Universities of Birmingham and Exeter.

Wessel Woldman

Co-Founder

Investors

Seed8 April 2024
£2.1M
AL
Ascension Life FundLead
Q
QantX
TF
The FSE Group
Empirical Ventures
Seed25 March 2021
£300K
QantX VenturesLead

Funding history

Seed8 April 2024

£2.1M

Neuronostics secures £2.1m seed funding led by Ascension Life Fund to accelerate international expansion.

The financing round will help the medical technology company advance its epilepsy diagnosis software towards US and Middle Eastern markets.

Seed25 March 2021

£300K

Neuronostics raises £300k in seed funding from QantX Ventures to advance clinical support systems.

The seed round was backed by private investors establishing QantX Ventures to fund clinical development.